Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Aurobindo Pharma Limited — Q4 FY25
Aurobindo Pharma delivered a strong Q4 FY25 with revenue of INR 8,382 crore (+11% YoY) and EBITDA of INR 1,792 crore (21.4% margin), driven by volume growth in US and Europe, stable pricing, and easing raw material costs.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma delivered a strong Q4 FY25 with revenue of INR 8,382 crore (+11% YoY) and EBITDA of INR 1,792 crore (21.4% margin), driven by volume growth in US and Europe, stable pricing, and easing raw material costs. Full-year revenue reached INR 31,724 crore (+9% YoY) with EBITDA margin expanding to 20.8%. US formulation grew 13% YoY to INR 4,072 crore, Europe grew 17% to INR 2,147 crore, and the injectable business rose 25% YoY. Management guided for high single-digit revenue growth in FY26 (excluding transient products) and aims to maintain current EBITDA margins, though tariff announcements in July 2025 add uncertainty. Key risks include the Pen-G plant fire disruption, potential US tariffs, and muted injectable growth in FY26 pending FDA clearance of Eugia-3.
ऑरोबिंदो फार्मा ने वित्त वर्ष 2025 की चौथी तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई 8,382 करोड़ रुपये रही, जो पिछले साल से 11% ज्यादा है। मुनाफा (EBITDA) 1,792 करोड़ रुपये यानी 21.4% मार्जिन पर रहा। इसकी वजह अमेरिका और यूरोप में बिक्री बढ़ना, कीमतें स्थिर रहना और कच्चे माल की लागत कम होना है। पूरे साल की कमाई 31,724 करोड़ रुपये (+9%) और मुनाफा मार्जिन 20.8% रहा। अमेरिका में दवा बिक्री 13% और यूरोप में 17% बढ़ी। इंजेक्टेबल दवाओं की बिक्री 25% बढ़ी। कंपनी अगले साल 7-9% कमाई बढ़ने की उम्मीद करती है, लेकिन जुलाई 2025 में टैरिफ (आयात शुल्क) की घोषणा से अनिश्चितता है। जोखिमों में पेन-जी प्लांट में आग, अमेरिकी टैरिफ और यूजिया-3 की मंजूरी में देरी शामिल है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Pen-G plant fire disruption
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Formulation Revenue (constant currency)
$470M
+9% YoY
US formulation revenue in constant currency terms for Q4 FY25.
Europe Formulation Revenue (constant currency)
€236M
+16% YoY
Europe formulation revenue in constant currency terms for Q4 FY25.
Net Cash Position
$42M
from net debt of $84M in Dec 2024
Company turned net cash positive in Q4 FY25 from net debt position.
R&D Spend as % of Revenue
5.1%
flat YoY
R&D expenditure for FY25 was 5.1% of revenue, mainly for clinical trials.
What Changed vs Last Quarter
NEW
High single-digit revenue growth in FY26 excluding transient products
Management expects revenue growth of 8-9% in FY26, excluding the contribution from transient products like Revlimid.
NEW
Maintain current EBITDA margins in FY26
The company internally aims to keep EBITDA margins at present levels (around 20.8%) for FY26.
UPDATED
China OSD plant to contribute revenues in FY26
The China plant, commercialized in FY25, is expected to contribute revenues in FY26 and turn breakeven or slightly positive.
UPDATED
US Dayton OSD plant commercialization in Q2 FY26
The US-based OSD plant at Dayton is expected to commence commercial manufacturing in Q2 of FY26.
DROPPED
FY25 EBITDA margin guidance of 21%-22%
Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and operational efficiencies.
DROPPED
Biosimilar launches in EU from July 2025
Following positive CHMP opinions, Filgrastim and Pegfilgrastim expected to launch in EU in Q2 FY26, with revenue bookings starting from that quarter.
NEW RISK
Pen-G plant fire disruption
A fire incident at the Pen-G facility in Kakinada has halted production; resumption depends on regulatory approvals, impacting FY26 revenue and margin assumptions.
NEW RISK
Potential US tariffs on pharmaceutical imports
Tariff announcements expected in July 2025 could impact US business; management declined to provide specific guidance until clarity emerges.
NEW RISK
Muted injectable growth in FY26 due to Eugia-3 remediation
Eugia-3 facility remains under FDA remediation; injectable growth is expected to be flat in FY26, with recovery only in FY27.
NEW RISK
Revlimid revenue decline in FY26
Revenue from Revlimid will be significantly lower in FY26 as the product faces increased competition and limited remaining supply.
RISK GONE
Generic Revlimid patent expiry impact
Patent expiry in January 2026 could lead to pricing erosion and market share loss; management acknowledged uncertainty but plans to continue supply post-expiry.
RISK GONE
Eugia injectables capacity ramp-up delays
Capacity utilization at Eugia remains at 50% due to supply challenges; any further delays in returning to normal run-rate could impact US injectable revenue.
RISK GONE
Biosimilar clinical trial delays
Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
RISK GONE
US tariff risk on pharmaceuticals
Potential US tariffs on pharmaceutical imports could impact margins; management believes existing US manufacturing footprint provides mitigation.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24, Q4 FY24
Management reiterated internal target for full-year EBITDA margin, implying H2 margins will be higher than H1.
Mentioned in Q1 FY25, Q2 FY25, Q3 FY24, Q3 FY25
Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
Mentioned in Q1 FY25, Q3 FY24, Q3 FY25
The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.
Mentioned in Q1 FY24, Q2 FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
Mentioned in Q1 FY24, Q1 FY25
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
Fast read
Guidance and risk preview
Management expects revenue growth of 8-9% in FY26, excluding the contribution from transient products like Revlimid.
A fire incident at the Pen-G facility in Kakinada has halted production; resumption depends on regulatory approvals, impacting FY26 revenue and mar...
View Risks →